Lenvatinib in unresectable HCC

Philip Philip, MD of Karmanos Cancer Institute discusses the use of lenvatinib in patients with unresectable hepatocellular carcinoma (HCC) at the 2017 Annual Meeting Annual Meeting in Chicago, IL.